Skip to content
OpenCapital
Get started

Solid Biosciences Inc. SLDB Cash & Equivalents

Cash & Equivalents at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$464.45M+92.8%
Biogen logo
BiogenBIIB
$3.38B+30.2%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$274.5M+35.8%
Insmed logo
InsmedINSM
$582.19M+44.4%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$753.1M+59.5%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$276.58M+137%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s cash & equivalents?
Solid Biosciences Inc. (SLDB) reported cash & equivalents of $297.1M in Q1 2026.
How has Solid Biosciences Inc.'s cash & equivalents changed year-over-year?
Solid Biosciences Inc.'s cash & equivalents increased by 41.1% year-over-year, from $210.63M to $297.1M.
What is the long-term trend for Solid Biosciences Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Solid Biosciences Inc.'s cash & equivalents has grown at a -17.3% compound annual growth rate (CAGR), from $154.74M to $59.9M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.